China’s National Medical Products Administration (NMPA) is the national regulator responsible for authorizing drug clinical trials conducted in mainland China. For any sponsor planning a China site as part of a multi-regional clinical trial (MRCT), or a China-only development program, the NMPA pathway is the equivalent gate that an FDA Investigational New Drug (IND) application or a PMDA Clinical Trial Notification represents in the United States and Japan respectively — except the underlying mechanics (an implicit-approval clock, a newer expedited track, and a genetic-material filing that runs in parallel) are distinct enough that sponsors used to other jurisdictions routinely misjudge the timeline and documentation burden.
This guide covers what NMPA actually reviews, the two live review timelines (60 working days and, since late 2025, an expedited 30-working-day track), the parallel Human Genetic Resources (HGR) filing that trips up many foreign sponsors, and how the China pathway fits into a broader multi-regional trial plan.
What NMPA is and what it governs
NMPA was formed in March 2018 when China’s State Council reorganized the former China Food and Drug Administration (CFDA) as part of a broader institutional restructuring; NMPA absorbed CFDA’s drug, biologic, medical device, and cosmetic regulatory functions. Within NMPA, drug clinical trial applications are technically reviewed by the Center for Drug Evaluation (CDE), the NMPA’s dedicated scientific review body — the entity a sponsor’s regulatory affairs team is actually corresponding with day to day, even though NMPA is the authorizing agency of record.
NMPA authorization is required before a drug or biologic (small molecule, traditional Chinese medicine, or biological product) can be administered to human subjects in a China-based trial. This guide covers the drug/biologic pathway; medical device clinical trials in China follow a related but separate NMPA process not covered here.
The core mechanism: implicit (deemed) approval
China’s Clinical Trial Application (CTA) review runs on an implicit approval model, sometimes called deemed approval: if CDE has not issued a rejection, hold, or request for additional information within the review clock, the application is treated as approved and the sponsor may proceed. This is a materially different mechanism from FDA’s IND process, where 30 calendar days of agency silence is itself the default clearance to proceed — NMPA’s version is calendar-driven in the same silence-equals-clearance sense, but on a longer clock and denominated in working days rather than calendar days.
The default review period is 60 working days from acceptance of a complete application. NMPA’s own reporting describes this 60-working-day implicit-approval mechanism, introduced in 2019, as having already compressed real average review times to roughly 50 working days in practice — sponsors should plan around the regulatory ceiling (60 working days) rather than the reported average, since actual review time varies by product complexity and whether CDE requests clarification.
The new 30-working-day expedited pathway (from late 2025)
In October 2025, NMPA published Announcement No. 86 of 2025, “Optimizing the Review and Approval Process for Clinical Trials of Innovative Drugs,” introducing an additional, faster track that sits on top of the existing 60-working-day mechanism rather than replacing it. Eligible applications are reviewed and approved within 30 working days of acceptance.
Per NMPA’s own policy interpretation of the announcement, an application qualifies for the 30-day track through one of three routes:
- Priority innovative drugs — products demonstrating significant clinical value and supported under China’s national full-chain policy framework for innovative drug development.
- Global/multi-regional development programs — drugs undergoing worldwide synchronized development or genuine international multi-center clinical trials, where the Phase III trial requires a Chinese principal investigator in a leadership role.
- Special categories — pediatric drugs, rare-disease (orphan) drugs, and innovative traditional Chinese medicines, as specifically published by CDE.
Two operational details matter for sponsors evaluating whether to use the fast track:
- If CDE cannot complete review within the 30-working-day window because of complex technical issues, the need for expert consultation, or a required meeting, it will notify the applicant via the Applicant’s Window within 20 working days of acceptance, and the review reverts to the standard 60-working-day timeline — not a rejection, but sponsors should not treat 30 days as a hard guarantee.
- Sponsors using the expedited track must commit to initiating the trial — defined as first-subject informed consent — within 12 weeks of approval, and must register progress on China’s Drug Clinical Trial Registration and Information Disclosure Platform. This condition is meant to keep the fast track reserved for genuinely trial-ready sponsors rather than used simply to reserve a queue position.
The expedited pathway does not relax safety or ICH-alignment expectations: CDE still requires the same Good Clinical Practice compliance, quality standards, and risk-management collaboration among sponsor, institution, investigator, and ethics committee that apply under the standard 60-day track.
The Human Genetic Resources (HGR) filing — a distinct, parallel requirement
A step that has no direct FDA or EMA equivalent, and that catches many first-time sponsors in China by surprise, is Human Genetic Resources (HGR) approval or filing. China separately regulates the collection, use, export, and international sharing of human genetic material (broadly, biological samples and the genomic/sequencing data derived from them) under its own Human Genetic Resources regulatory framework, independent of the drug-approval pathway.
Regulatory oversight of HGR moved from the Ministry of Science and Technology (MOST) to the National Health Commission (NHC) effective May 1, 2024. As of 2026, NHC has continued refining the implementing rules, including a 2026 consultation draft aimed at narrowing the scope of what counts as regulated HGR data (excluding routine clinical, imaging, protein, and metabolic data, and focusing the strictest controls on nucleic-acid sequence data) and adding a fast-track same/next-working-day filing confirmation for international collaborative trials that do not involve exporting HGR information out of China. [Regulatory detail here is drawn from secondary legal/compliance reporting on NHC’s 2025-2026 rule updates, not independently pulled from the primary Chinese-language regulation text; sponsors should confirm current HGR scope and timelines directly with NHC or in-country regulatory counsel before relying on specifics.]
The practical implication: a foreign-sponsored or internationally-collaborative trial in China typically needs to plan for an HGR approval or filing track that runs in parallel with, not sequentially after, the NMPA/CDE clinical trial review — treating it as an afterthought after CTA approval is a common source of site-activation delay.
Good Clinical Practice and ethics review
Trial conduct in China is governed by China’s own Good Clinical Practice regulation (issued jointly by NMPA and NHC, effective July 1, 2020), which is substantively aligned with ICH GCP (ICH E6(R2)/moving toward E6(R3) principles) but is its own binding domestic regulation, not a direct adoption of the ICH text. Institutional ethics committee approval at each participating site is required in parallel with, and independent of, NMPA/CDE authorization — NMPA approval of the CTA does not substitute for site-level ethics review, and vice versa.
How this compares to other jurisdictions
For sponsors coordinating a multi-regional trial, it helps to see China’s pathway alongside the mechanisms it is most often compared to:
- United States (FDA): a 30-calendar-day implicit clearance for the initial IND, versus NMPA’s 60-working-day default (or 30-working-day expedited track for qualifying innovative drugs).
- Japan (PMDA): a 30-day initial review window for the Clinical Trial Notification (CTN), notification-based rather than implicit-approval-based in structure, but similarly fast relative to NMPA’s standard track.
- Cross-jurisdiction trial design: sponsors running a genuine multi-regional clinical trial spanning China alongside the US, EU, or Japan should read this alongside ICH M4 (CTD) for how submission dossiers are harmonized across authorities, and ICH M11 for the harmonized protocol template increasingly used across regions including China.
Who manages this process
In practice, the NMPA/CDE submission is typically owned by a sponsor’s China regulatory affairs function or a China-based CRO acting on the sponsor’s behalf, working alongside in-country legal/compliance counsel for the separate HGR track and the site’s institutional ethics committee for local ethics approval. For a multinational sponsor, the research administration function’s role is usually coordination and timeline planning — sequencing the NMPA/CDE review, the HGR filing, ethics committee approval, and site activation so that none of these parallel tracks becomes the unplanned critical path.
Frequently asked questions
Is NMPA approval the same as an FDA IND?
Functionally comparable — both are the required regulatory authorization before administering an investigational drug to human subjects — but mechanically different. FDA’s IND uses a 30-calendar-day implicit clearance; NMPA’s Clinical Trial Application (CTA) uses a 60-working-day default implicit-approval clock, with an additional 30-working-day expedited track available for qualifying innovative drugs since late 2025.
How long does NMPA clinical trial approval actually take?
Up to 60 working days by default, though NMPA has reported average actual review closer to 50 working days. Qualifying innovative drugs (priority innovative therapies, genuine multi-regional/global development programs with Chinese PI leadership on Phase III, or specific pediatric/rare-disease/traditional-Chinese-medicine categories) can be reviewed within 30 working days under the pathway introduced by NMPA Announcement No. 86 of 2025.
Does every China trial need Human Genetic Resources (HGR) approval?
Not necessarily every trial, but any trial involving the collection, use, or international transfer of human genetic material (particularly nucleic-acid sequence data) typically needs to go through the HGR approval or filing process administered by the National Health Commission, separately from the NMPA/CDE clinical trial review. Scope has been narrowing under 2025-2026 rule updates, so sponsors should confirm current applicability for their specific trial design rather than assume it does or doesn’t apply.
What happens if CDE can’t finish the 30-working-day expedited review in time?
CDE notifies the applicant through the Applicant’s Window within 20 working days of acceptance if complex technical issues, expert consultation, or a required meeting mean the review can’t be completed on the expedited timeline. The review then reverts to the standard 60-working-day track rather than being rejected outright.
Where does trial registration happen after NMPA approval?
Sponsors register and disclose trial progress on China’s Drug Clinical Trial Registration and Information Disclosure Platform, which is a distinct system from international registries such as ClinicalTrials.gov — sponsors running a China arm of a multi-regional trial typically need to plan for registration on both.
Key takeaways
- NMPA’s Center for Drug Evaluation (CDE) reviews drug/biologic Clinical Trial Applications under a 60-working-day implicit-approval default.
- An additional 30-working-day expedited pathway has applied since NMPA Announcement No. 86 of 2025, for priority innovative drugs, genuine global/multi-regional programs with Chinese Phase III PI leadership, and specific pediatric/rare-disease/TCM categories.
- Expedited-track sponsors must commit to first-subject consent within 12 weeks of approval.
- Human Genetic Resources (HGR) approval/filing, administered by NHC since May 2024, is a separate, parallel requirement for trials handling human genetic material — plan it alongside, not after, the NMPA review.
- China’s own GCP regulation (effective July 2020) and site-level ethics committee approval both run independently of, and in parallel with, NMPA/CDE authorization.
